Do the benefits of subcutaneous immunoglobulin therapy for secondary hypogammaglobulinemia in ANCA vasculitis extend beyond infection prevention?


Journal article


Bryce M. Churilla, Faten Aqeel, A. Azar, B. Antiochos, P. Seo, D. Hellmann, D. Geetha
Kidney International, 2022

Semantic Scholar DOI PubMed
Cite

Cite

APA   Click to copy
Churilla, B. M., Aqeel, F., Azar, A., Antiochos, B., Seo, P., Hellmann, D., & Geetha, D. (2022). Do the benefits of subcutaneous immunoglobulin therapy for secondary hypogammaglobulinemia in ANCA vasculitis extend beyond infection prevention? Kidney International.


Chicago/Turabian   Click to copy
Churilla, Bryce M., Faten Aqeel, A. Azar, B. Antiochos, P. Seo, D. Hellmann, and D. Geetha. “Do the Benefits of Subcutaneous Immunoglobulin Therapy for Secondary Hypogammaglobulinemia in ANCA Vasculitis Extend beyond Infection Prevention?” Kidney International (2022).


MLA   Click to copy
Churilla, Bryce M., et al. “Do the Benefits of Subcutaneous Immunoglobulin Therapy for Secondary Hypogammaglobulinemia in ANCA Vasculitis Extend beyond Infection Prevention?” Kidney International, 2022.


BibTeX   Click to copy

@article{bryce2022a,
  title = {Do the benefits of subcutaneous immunoglobulin therapy for secondary hypogammaglobulinemia in ANCA vasculitis extend beyond infection prevention?},
  year = {2022},
  journal = {Kidney International},
  author = {Churilla, Bryce M. and Aqeel, Faten and Azar, A. and Antiochos, B. and Seo, P. and Hellmann, D. and Geetha, D.}
}


Share


Follow this website


You need to create an Owlstown account to follow this website.


Sign up

Already an Owlstown member?

Log in